Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

BACKGROUND: Some patients with metastatic breast cancer (MBC) stay on endocrine therapy (ET) for years and others progress quickly. Serum thymidine kinase activity (TKa), an indicator of cell-proliferation, is a potential biomarker for monitoring ET and predicting MBC outcome. We have previously rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergqvist, Mattias, Nordmark, Adrian, Williams, Amy, Paoletti, Costanza, Barlow, William, Cobain, Erin F., Mehta, Rita S., Gralow, Julie R., Hortobagyi, Gabriel N., Albain, Kathy S., Pusztai, Lajos, Sharma, Priyanka, Godwin, Andrew K., Thompson, Alastair M., Hayes, Daniel F., Rae, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681159/
https://www.ncbi.nlm.nih.gov/pubmed/36647745
http://dx.doi.org/10.1080/1354750X.2023.2168063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681159/
https://www.ncbi.nlm.nih.gov/pubmed/36647745
http://dx.doi.org/10.1080/1354750X.2023.2168063

Ejemplares similares